ClinicalTrials.gg
RecruitingNCT06846320Updated Jun 17, 2026

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

A Phase 2 interventional study of ABBV-932 and Placebo for ABBV-932 in Generalized Anxiety Disorder (GAD), sponsored by AbbVie. Recruiting at 52 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Planned enrollment
50th of 234
315 · median 90
Started
2025
with 14 others
Phase 2
21 of 265
5 open now
Primary completion
2026-11
later than 16 of 52 live
Registered
242nd of 265
by date
Lead sponsor
5 of 265
AbbVie

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 50th largest by planned enrollment of the 234 interventional ones that give a count, is one of 15 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 16 of the 52 other live ones, and was the 242nd registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.

ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico.

Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Generalized Anxiety Disorder (GAD)

Keywords

  • LEGATO - (GAD)
  • Generalized Anxiety Disorder (GAD)
  • ABBV-932
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet , Fifth Edition, Text Revision (DSM-5-TR) criteria for generalized anxiety disorder (GAD) confirmed by the Mini International Neuropsychiatric Interview (MINI).
  • Currently taking protocol-specified antidepressant therapies (ADT) for GAD with an inadequate response to an adequate dose (per label) and duration (>= 8 weeks) as verified by a baseline Hamilton Anxiety Rating Scale (HAM-A) total score >= 20 and Clinical Global Impression of Severity Scale (CGI-S GAD) >= 4.

Exclusion criteria

Exclusion Criteria:

  • Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score >= 20.
  • New diagnosis or exacerbation of major depression in the last 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
315 participants (estimated)

Study arms

  • Experimental
    ABBV-932 Dose A

    Participants will receive ABBV-932 dose A in addition to prescribed antidepressant therapies (ADTs).

    Drug: ABBV-932 · Drug: Antidepressant Therapy (ADT)

  • Experimental
    ABBV-932 Dose B

    Participants will receive ABBV-932 dose B in addition to prescribed antidepressant therapies (ADTs).

    Drug: ABBV-932 · Drug: Antidepressant Therapy (ADT)

  • Placebo comparator
    Placebo for ABBV-932

    Participants will receive placebo for ABBV-932 in addition to prescribed antidepressant therapies (ADTs).

    Drug: Placebo for ABBV-932 · Drug: Antidepressant Therapy (ADT)

Interventions

  • Oral Capsule

  • DrugPlacebo for ABBV-932

    Oral Capsule

  • DrugAntidepressant Therapy (ADT)

    Standard of care

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 10 weeks

  2. Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

    The HAM-A is a 14-item, clinician-reported measure used to quantify and categorize the participant's anxiety over the past week. Items are rated on a 5-point Likert rating scale. The HAM-A total score ranges from 0 to 56, with higher scores indicating greater anxiety severity.

    Time frame: Up to approximately 6 weeks

Secondary outcomes

  1. Change from Baseline in Penn State Worry Questionnaire-10 (PSWQ-10) Total Score

    The PSWQ-10 is a 10-item, participant-reported measure of the tendency of an individual to worry, the excessiveness or intensity of worry, and the tendency for the worry to be generalized and not restricted to a small number of situations. Items are rated from 0 to 6 (0, never; 6, almost always). Total scores range from 0 to 60, with higher scores indicating greater worry.

    Time frame: Up to approximately 6 weeks

  2. Change from Baseline in Clinical Global Impression of Severity Scale (CGI-S) Generalized Anxiety Disorder (GAD)

    The CGI-S GAD is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the participant population. The measure uses a 7-point Likert rating scale, with higher scores indicating greater anxiety severity.

    Time frame: Up to approximately 6 weeks

  3. Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

    The HAM-A is a 14-item, clinician-reported measure used to quantify and categorize the participant's anxiety over the past week. Items are rated on a 5-point Likert rating scale. The HAM-A total score ranges from 0 to 56, with higher scores indicating greater anxiety severity.

    Time frame: Up to approximately 4 weeks

  4. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

    Time frame: Up to approximately 6 weeks

  5. Percentage of Participants in Remission

    Remission is defined as HAM-A total score \<=7.

    Time frame: Up to approximately 6 weeks

  6. Percentage of Participants with HAM-A Response

    HAM-A response is defined as \>= 50% reduction from baseline in HAM-A total score

    Time frame: Up to approximately 6 weeks

  7. Percentage of Participants with Clinical Global Impression of Change (CGI-C) GAD Responder Status of "Much Better" or "Moderately Better"

    The CGI-C GAD is a clinician-rated scale that measures the overall change in a participant's GAD symptoms since initial receipt of the study medication. The participant is rated on a 7-point Likert scale ranging from "Much better" (1) to "Much worse" (7).

    Time frame: Up to approximately 6 weeks

  8. Change from Baseline in Patient Global Impression of Severity Scale (PGI-S) Generalized Anxiety Disorder (GAD)

    The PGI-S GAD is a single, patient-reported item that assesses the subject's perceived level of GAD symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity of GAD symptoms.

    Time frame: Up to approximately 6 weeks

  9. Percentage of Participants with Patient Global Impression of Change Scale (PGI-C) Generalized Anxiety Disorder (GAD) Responder Status of "Much Better" or "Moderately Better"

    The PGI-C GAD is a single, patient-reported item that assesses the subject's perceived overall change in their GAD symptoms since they started taking the study medication. The measure uses a 7-point Likert rating scale with responses ranging from "much better" (1) to "much worse" (7). Higher scores indicate worse GAD symptoms

    Time frame: Up to approximately 6 weeks

  10. Change from Baseline in Patient Global Impression of Severity Scale (PGI-S) Worry

    The PGI-C Worry is a single, patient-reported item that assesses the subject's perceived overall change in their worry since they started taking the study medication. The measure uses a 7-point Likert rating scale with responses ranging from "much less worried" (1) to "much more worried" (7). Higher scores indicate more worry.

    Time frame: Up to approximately 6 weeks

  11. Percentage of Participants with Patient Global Impression of Change Scale (PGI-C) Worry Responder Status of "Much Better" or "Moderately Better"

    The PGI-C Worry is a single, patient-reported item that assesses the subject's perceived overall change in their worry since they started taking the study medication. The measure uses a 7-point Likert rating scale with responses ranging from "much less worried" (1) to "much more worried" (7). Higher scores indicate more worry.

    Time frame: Up to approximately 6 weeks

07

Study locations

50 of 52 sites recruiting
  • University of Alabama - Huntsville Regional Medical Campus /ID# 267818
    Huntsville, Alabama 35801, United States
    Recruiting
    • Site Coordinator · Contact256-551-4431
  • Ima Clinical Research Phoenix (Alea) /ID# 275737
    Phoenix, Arizona 85012, United States
    Recruiting
  • Noble Clinical Research /ID# 267952
    Tucson, Arizona 85704, United States
    Completed

    Not enrolling at this site — choose another above.

  • Advanced Research Center /ID# 267874
    Anaheim, California 92805, United States
    Recruiting
    • Site Coordinator · Contact714-999-6688
  • Axiom Research /ID# 267814
    Colton, California 92324, United States
    Recruiting
    • Site Coordinator · Contact909-824-2325
  • Sun Valley Research Center /ID# 267864
    Imperial, California 92251, United States
    Recruiting
    • Site Coordinator · Contact760-545-0123
  • Synergy San Diego /ID# 267879
    Lemon Grove, California 91945, United States
    Recruiting
  • Alliance for Research Alliance for Wellness /ID# 267911
    Long Beach, California 90807, United States
    Recruiting
  • NRC Research Institute DTLA /ID# 267832
    Los Angeles, California 90015, United States
    Recruiting
    • Site Coordinator · Contact714-289-1100
  • Excell Research /ID# 267918
    Oceanside, California 92056, United States
    Recruiting
  • Inland Psychiatric Medical Group /ID# 268598
    Temecula, California 92591, United States
    Recruiting
  • Sunwise Clinical Research /ID# 267863
    Walnut Creek, California 94596, United States
    Recruiting
    • Site Coordinator · Contact925-298-5147
  • Connecticut Clinical Research - Cromwell /ID# 271241
    Cromwell, Connecticut 06416, United States
    Recruiting
  • Cns Healthcare - Jacksonville /ID# 268588
    Jacksonville, Florida 32256, United States
    Recruiting
  • Accel Research Sites Network - St. Pete /ID# 267821
    Largo, Florida 33777, United States
    Recruiting
    • Site Coordinator · Contact321-878-9477
  • K2 Medical Research, LLC /ID# 267841
    Maitland, Florida 32751, United States
    Recruiting
  • GMI Florida - Central Miami Medical Institute /ID# 267839
    Miami, Florida 33125, United States
    Recruiting
    • Site Coordinator · Contact305-547-2011
  • Allied Biomedical Res Inst Inc /ID# 267813
    Miami, Florida 33155, United States
    Recruiting
    • Site Coordinator · Contact305-643-8400
  • Apg Research /ID# 271707
    Orlando, Florida 32803, United States
    Recruiting
  • Psych Atlanta /ID# 267878
    Marietta, Georgia 30060, United States
    Recruiting
  • iResearch Savannah /ID# 267865
    Savannah, Georgia 31405, United States
    Recruiting
    • Site Coordinator · Contact912-744-0800
  • University of Chicago Medical Center /ID# 275131
    Chicago, Illinois 60637, United States
    Recruiting
  • Collective Medical Research /ID# 272015
    Overland Park, Kansas 66210, United States
    Recruiting
  • CenExel /ID# 267853
    Gaithersburg, Maryland 20877-1407, United States
    Recruiting
    • Site Coordinator · Contact301-251-4702
  • Elixia - Springfield /ID# 267815
    Springfield, Massachusetts 01103, United States
    Recruiting
  • Psychiatric Care And Research Center /ID# 271701
    O'Fallon, Missouri 63368, United States
    Recruiting
  • Saint Charles Psychiatric Associates /ID# 271202
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Arch Clinical Trials /ID# 267851
    St Louis, Missouri 63125, United States
    Recruiting
  • Ima Clinical Research Las Vegas (SMO/Network/Consortium) /ID# 275731
    Las Vegas, Nevada 89102, United States
    Recruiting
  • Duplicate_Oasis Clinical Research, LLC /ID# 267953
    Las Vegas, Nevada 89121, United States
    Completed

    Not enrolling at this site — choose another above.

  • Princeton Medical Institute /ID# 267877
    Princeton, New Jersey 08540, United States
    Recruiting
    • Site Coordinator · Contact609-921-3555
  • Bio Behavioral Health /ID# 267919
    Toms River, New Jersey 08755, United States
    Recruiting
  • Integrative Clinical Trials /ID# 279519
    Brooklyn, New York 11229, United States
    Recruiting
  • New Hope Clinical Research - Inpatient unit /ID# 267810
    Charlotte, North Carolina 28211, United States
    Recruiting
    • Site Coordinator · Contact980-209-9784
  • Quest Therapeutics of Avon /ID# 267829
    Avon Lake, Ohio 44012-1004, United States
    Recruiting
    • Site Coordinator · Contact440-949-9115
  • University Of Cincinnati Medical Center /ID# 271704
    Cincinnati, Ohio 45219, United States
    Recruiting
  • The Ohio State University /ID# 267924
    Columbus, Ohio 43210, United States
    Recruiting
  • Sooner Clinical Research /ID# 267881
    Oklahoma City, Oklahoma 73116, United States
    Recruiting
  • Lehigh Center for Clinical Research /ID# 267908
    Allentown, Pennsylvania 18103, United States
    Recruiting
  • Suburban Research Associates /ID# 267868
    West Chester, Pennsylvania 19380-4370, United States
    Recruiting
    • Site Coordinator · Contact610-891-7200
  • Coastal Carolina Research Center, LLC /ID# 267826
    Charleston, South Carolina 29492, United States
    Recruiting
    • Site Coordinator · Contact321-878-9477
  • Psychiatric Consultants - Franklin /ID# 275133
    Franklin, Tennessee 37067, United States
    Recruiting
    • Site Coordinator · Contact615-807-4023
  • FutureSearch Trials of Dallas /ID# 267870
    Dallas, Texas 75231, United States
    Recruiting
  • Relaro Medical Trials /ID# 270241
    Dallas, Texas 75243, United States
    Recruiting
  • Perceptive Pharma Research /ID# 267836
    Richmond, Texas 77407, United States
    Recruiting
    • Site Coordinator · Contact346-467-2182
  • Family Psychiatry Of The Woodlands /ID# 275173
    The Woodlands, Texas 77381, United States
    Recruiting
  • Grayline Research Center /ID# 267811
    Wichita Falls, Texas 76309, United States
    Recruiting
    • Site Coordinator · Contact940-322-1131
  • Northwest Clinical Research Center /ID# 267916
    Bellevue, Washington 98007, United States
    Recruiting
  • Core Clinical Research /ID# 270058
    Everett, Washington 98201, United States
    Recruiting
  • Inspira Clinical Research /ID# 267822
    San Juan, 00918-3014, Puerto Rico
    Recruiting
  • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267793
    San Juan, 00918, Puerto Rico
    Recruiting
    • Site Coordinator · Contact787-763-9312
  • BDH Research /ID# 267787
    San Juan, 00927, Puerto Rico
    Recruiting
    • Site Coordinator · Contact787-523-9808
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Apr 29, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06846320
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Apr 29, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jun 17, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-932

Start the discussion